340 related articles for article (PubMed ID: 26619226)
1. Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?
Sharma H; Santra S; Dutta A
Future Med Chem; 2015; 7(17):2385-406. PubMed ID: 26619226
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
Lee KH; Park CE; Min KH; Shin YJ; Chung CM; Kim HH; Yoon HJ; Won-Kim ; Ryu EJ; Shin YJ; Nam HS; Cho JW; Lee HY
Bioorg Med Chem Lett; 2010 Sep; 20(18):5567-71. PubMed ID: 20724153
[TBL] [Abstract][Full Text] [Related]
3. Triple uptake inhibitors: therapeutic potential in depression and beyond.
Chen Z; Skolnick P
Expert Opin Investig Drugs; 2007 Sep; 16(9):1365-77. PubMed ID: 17714023
[TBL] [Abstract][Full Text] [Related]
4. Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.
Santra S; Sharma H; Vedachalam S; Antonio T; Reith M; Dutta A
Bioorg Med Chem; 2015 Feb; 23(4):821-8. PubMed ID: 25593099
[TBL] [Abstract][Full Text] [Related]
5. Triple reuptake inhibitors: a patent review (2006 - 2012).
Shao L; Li W; Xie Q; Yin H
Expert Opin Ther Pat; 2014 Feb; 24(2):131-54. PubMed ID: 24289044
[TBL] [Abstract][Full Text] [Related]
6. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
[TBL] [Abstract][Full Text] [Related]
7. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors.
Guiard BP; El Mansari M; Blier P
Curr Drug Targets; 2009 Nov; 10(11):1069-84. PubMed ID: 19702555
[TBL] [Abstract][Full Text] [Related]
8. 2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.
Carter DS; Cai HY; Lee EK; Iyer PS; Lucas MC; Roetz R; Schoenfeld RC; Weikert RJ
Bioorg Med Chem Lett; 2010 Jul; 20(13):3941-5. PubMed ID: 20570146
[TBL] [Abstract][Full Text] [Related]
9. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.
Prins J; Olivier B; Korte SM
Expert Opin Investig Drugs; 2011 Aug; 20(8):1107-30. PubMed ID: 21682663
[TBL] [Abstract][Full Text] [Related]
10. The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.
Dutta AK; Gopishetty B; Gogoi S; Ali S; Zhen J; Reith M
Eur J Pharmacol; 2011 Dec; 671(1-3):39-44. PubMed ID: 21963455
[TBL] [Abstract][Full Text] [Related]
11. 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.
Micheli F; Cavanni P; Andreotti D; Arban R; Benedetti R; Bertani B; Bettati M; Bettelini L; Bonanomi G; Braggio S; Carletti R; Checchia A; Corsi M; Fazzolari E; Fontana S; Marchioro C; Merlo-Pich E; Negri M; Oliosi B; Ratti E; Read KD; Roscic M; Sartori I; Spada S; Tedesco G; Tarsi L; Terreni S; Visentini F; Zocchi A; Zonzini L; Di Fabio R
J Med Chem; 2010 Jul; 53(13):4989-5001. PubMed ID: 20527970
[TBL] [Abstract][Full Text] [Related]
12. Differences in mechanism of action between current and future antidepressants.
Stahl SM; Grady MM
J Clin Psychiatry; 2003; 64 Suppl 13():13-7. PubMed ID: 14552651
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor.
Hou J; Xing Y; Zuo D; Wu Y; Tian J; Meng Q; Yang M
Physiol Behav; 2015 Jan; 138():141-9. PubMed ID: 25447484
[TBL] [Abstract][Full Text] [Related]
14. Designing new treatments for depression and anxiety.
Chen Z; Yang J; Tobak A
IDrugs; 2008 Mar; 11(3):189-97. PubMed ID: 18311656
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
Skolnick P; Krieter P; Tizzano J; Basile A; Popik P; Czobor P; Lippa A
CNS Drug Rev; 2006; 12(2):123-34. PubMed ID: 16958986
[TBL] [Abstract][Full Text] [Related]
16. D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD like effects in rats.
Dutta AK; Santra S; Harutyunyan A; Das B; Lisieski MJ; Xu L; Antonio T; Reith MEA; Perrine SA
Eur J Pharmacol; 2019 Nov; 862():172632. PubMed ID: 31473161
[TBL] [Abstract][Full Text] [Related]
17. Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.
Sharma H; Santra S; Debnath J; Antonio T; Reith M; Dutta A
Bioorg Med Chem; 2014 Jan; 22(1):311-24. PubMed ID: 24315194
[TBL] [Abstract][Full Text] [Related]
18. The many different faces of major depression: it is time for personalized medicine.
Korte SM; Prins J; Krajnc AM; Hendriksen H; Oosting RS; Westphal KG; Korte-Bouws GA; Olivier B
Eur J Pharmacol; 2015 Apr; 753():88-104. PubMed ID: 25592320
[TBL] [Abstract][Full Text] [Related]
19. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression.
Trivedi MH; Hollander E; Nutt D; Blier P
J Clin Psychiatry; 2008 Feb; 69(2):246-58. PubMed ID: 18363453
[TBL] [Abstract][Full Text] [Related]
20. Development of new antidepressants.
Sambunaris A; Hesselink JK; Pinder R; Panagides J; Stahl SM
J Clin Psychiatry; 1997; 58 Suppl 6():40-53. PubMed ID: 9227672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
